viDA Therapeutics Inc Information

viDA Therapeutics, Inc. (viDA), is developing first-in-class drugs targeting granzymes for the treatment of inflammatory diseases characterized by epithelial barrier dysfunction. The accumulation of Granzyme B (GzmB),a serine protease, is involved in the dysfunction/disruption of the epithelium. viDA’s lead drug VTI-1002 is a potent inhibitor of GzmB that can be delivered topically. Initial programs in ophthalmology and dermatology. viDA is developing a high value platform. There are 5 granzymes in humans. Initial focus is Granzyme B (GzmB), a unique serine protease shown to play a causative role in a number of chronic inflammatory/autoimmune disease indications. Advancement of topical first in class GzmB inhibitor into the dermatology arena allows for establishment of GzmB as a validated, valuable clinical target. Significant value will be realized with a first in class dermatology product being used broadly in a number of skin disease scenarios including dermatitis, thermal, chemical and radiation injuries, and autoimmune disease. Clinical validation of GzmB as a therapeutic target will provide additional credibility to expand beyond dermatology. With safety and efficacy data in hand, alongside the addition of oral/systemic GzmB inhibitors, the Company will be able create significant broader platform value as it addresses additional chronic age-related inflammatory and autoimmune diseases.